Updated WHO policy recommendation: Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria
Primaquine potentially has a major role in reducing malaria transmission, especially in efforts to eliminate Plasmodium falciparum malaria. The population benefits of reducing malaria transmission by gametocytocidal drugs require that a very high proportion of patients receive these medicines.
Based on the review of the WHO Evidence Review Group, the Malaria Policy Advisory Committee (MPAC) recommends the following:
- In: (1) areas threatened by artemisinin resistance where single dose primaquine as a gametocytocide for P. falciparum malaria is not being implemented, and (2) elimination areas which have not yet adopted primaquine as a gametocytocide for P. falciparum malaria:
- A single 0.25 mg base/kg primaquine dose should be given to all patients with parasitologically-confirmed P. falciparum malaria on the first day of treatment in addition to an ACT, except for pregnant women and infants <1 year of age.
Relevant considerations for the programmatic implementation of these recommendations are provided in the complementary policy brief.
- Policy brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria
WHO Evidence Review Group: The safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide